Carl Sullivan - Author for 24/7 Wall St.
Lastest Stories by Carl Sullivan
Analysts like Lyft but it’s battling states over driver classification and the coronavirus has hit ridership hard.
Published:
Chesapeake Energy stock has had a good run this week as oil rebounds but analysts seem much more bearish than investors.
Published:
Altria wants to diversify into e-cigarettes and legal pot, but faces regulatory action, patent litigation and coronavirus-related setbacks.
Published:
Aphria stays strong while Green Growth, which tried to buy it, goes bust. Canadian rival Aurora buys U.S. hemp retailer Reliva.
Published:
As TikTok’s popularity surges the clock may be ticking for Snap and other rivals, but the Chinese-owned company faces regulatory pressure in the U.S.
Published:
Last Updated:
AT&T stock has underperfomed against rivals Verizon and T-Mobile but the rollout of 5G networks could change the competitive landscape.
Published:
High times in hard times? Tilray says pot should be seen as a consumer staple rather than an indulgence.
Published:
Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing on the stock.
Published:
As the pandemic impacts meat-processing capacity, investors might have an appetite for alternatives such as Beyond Meat.
Published:
Uber is cutting more jobs and looking to boost food delivery as the pandemic pummels the ride-sharing business.
Published:
Even as Ford plants reopen the coronavirus has cut demand and rattled the supply chain, as well as shareholders.
Published:
Facing regulatory probes at the federal and state levels, Facebook plays defense with Oversight Board and offense with American Edge lobbying group.
Published:
The economic hit from the coronavirus pandemic is showing up in mortgage delinquencies and that’s bad for Fannie Mae.
Published:
Canadian pot company Aphria is well positioned in the medical and recreational sectors. It has eyes on Europe but the coronavirus has stalled legalization efforts in the U.S.
Published:
Cannabis stocks have disappointed but the coronavirus lockdown might boost consumer demand.
Published: